European Society for Medical Oncology Breast Cancer Congress (ESMO Breast) | Conference

First-Line Ribociclib Combo Yields Significant OS Benefit Vs Fulvestrant in Postmenopausal HR+, HER2- Advanced Breast Cancer
May 05, 2022

Updated findings from the phase 3 MONALESSA-3 trial identified a significant overall survival benefit among postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who were treated with ribociclib and fulvestrant vs matched placebo.

Dr. Hurvitz Discusses Therapy Options for Breast Cancer
October 17, 2019

CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer. 

Dr. Schmid Discusses the KEYNOTE-522 Trial
October 16, 2019

CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.

Dr. Dent Discusses Immunotherapy in Early-Stage Breast Cancer
October 11, 2019

Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.

Dr. Emens Discusses Overall Survival in HER2+ Breast Cancer
October 08, 2019

Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.

Two Studies Confirm OS Benefit of CDK4/6 Inhibitors in Breast Cancer
September 30, 2019

Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.

Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
September 30, 2019

Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.